Skip to main content

TERN

Stock
Health Care
Biotechnology

Performance overview

TERN Price
Price Chart

Forward-looking statistics

Beta
0.49
Risk
75.37%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Company info

SectorHealth Care
IndustryBiotechnology
Employees55
Market cap$462.4M

Fundamentals

Enterprise value-$7.3M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.38

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.08
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth+0.8
Credit+8.6
Liquidity-3.5
Inflation-3.0
Commodities-2.2
Interest Rates+0.7

Valuation

Dividend yield0.00%
PEG Ratio-3.11
Price to sales
P/E Ratio-3.11
Enterprise Value to Revenue
Price to book1.16

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day
Ex. dividend day

News

Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround

Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research (April 7, 2025)
Top 3 Health Care Stocks You'll Regret Missing In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (November 19, 2024)
The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

Wall Street has been focused on Novo Nordisk, Eli Lilly and other large drugmakers hoping to join the weight loss drug market, such as Pfizer, Roche and Amgen.

CNBC (January 17, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free